HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy-Reference-Cited by-同舟云学术

HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy

Published:2018-03-29 Issue:5 Volume:218 Page:688-697
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Wijting Ingeborg E A¹,Lungu Cynthia²,Rijnders Bart J A¹,van der Ende Marchina E¹,Pham Hanh T³⁴,Mesplede Thibault³⁴,Pas Suzan D²,Voermans Jolanda J C²,Schuurman Rob⁵,van de Vijver David A M C²,Boers Patrick H M²,Gruters Rob A²,Boucher Charles A B²,van Kampen Jeroen J A²

Affiliation:

1. Department of Internal Medicine and Infectious Diseases, Erasmus MC, Rotterdam, the Netherlands

2. Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands

3. McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada

4. Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montreal, Canada

5. Division of Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/218/5/688/25206918/jiy176.pdf

Reference45 articles.

1. Quantitative evaluation of the antiretroviral efficacy of dolutegravir;Laskey;JCI Insight,2016

2. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance;Brenner;Virus Res,2017

3. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial;Walmsley;J Acquir Immune Defic Syndr,2015

4. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO;Molina;J Int AIDS Soc,2014

5. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial;Raffi;Lancet Infect Dis,2013

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brief Report: Characterizing HIV Drug Resistance in Cases of Vertical Transmission in the VESTED Randomized Antiretroviral Treatment Trial;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-08-01

2. Reverse transcription of HIV-1 2-LTR circle transcripts does frequently cause 3'-polypurine tract mutations implicated in dolutegravir resistance;Journal of Virology;2024-06-13

3. Brief Histories of Retroviral Integration Research and Associated International Conferences;Viruses;2024-04-13

4. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review;Viruses;2024-03-04

5. Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors;Science Advances;2024-03